Gastric antisecretory when oral route is not possible eg, GERD in patients w/ esophagitis &/or severe reflux symptoms; healing of gastric ulcers associated w/ NSAID therapy. Short-term maintenance of haemostasis & prevention of rebleeding in patients following therapeutic endoscopy for acute bleeding, gastric or duodenal ulcers.
IV inj or infusionAdultGastric antisecretory 20-40 mg once daily. Reflux esophagitis 40 mg once daily. Symptomatic treatment for reflux disease, healing of gastric ulcer associated w/ NSAIDs therapy 20 mg once daily. Maintenance of haemostasis & prevention of rebleeding of gastric & duodenal ulcer 80 mg as bolus infusion over 30 min, followed by continuous IV infusion of 8 mg/hr for 3 days (72 hr). Severe liver impairmentGERD Max: 20 mg daily; Bleeding ulcers Initially 80 mg as bolus infusion, followed by 4 mg/hr continuous IV infusion for 71.5 hr.
Malignancy should be excluded if significant unintentional wt loss, recurrent vomiting, dysphagia, haematemesis or melena & gastric ulcer is suspected or present. Concomitant use w/ clopidogrel should be avoided. Patients at risk for developing osteoporosis or osteoporotic fractures. Severe renal insufficiency. Pregnancy. Not to be used during breast-feeding. Not to be used in childn & adolescents.
Decreased absorption of ketoconazole, itraconazole & erlotinib. Increased absorption & bioavailability of digoxin. Increased trough plasma levels of phenytoin in epileptic patients. Decreased exposure to the active metabolite of clopidogrel & max inhibition of (ADP induced) platelet aggregation. Increased MTX levels. Decreased serum levels of atazanavir & nelfinavir. Doubling exposure in combination of CYP2C19 & CYP3A4 inhibitors eg, voriconazole, clarithromycin. Decreased serum levels w/ rifampicin & St. John's wort.
A02BC05 - esomeprazole ; Belongs to the class of proton pump inhibitors. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Sign Out
